Kidney Week 2017: Pathogenic Role of V2R Signaling in Renal Cell Carcinoma
In a study presented at Kidney Week 2017 (Abstract FR-PO247), researchers from the University of Kansas Medical Center, Kansas City, found that vasopressin type 2 receptor (V2R) signaling plays a pathogenic role in tumor progression in patients with renal cell carcinoma. With this finding, Reena Rao, PhD, and colleagues suggested that V2R may prove to be a novel therapeutic target for patients with renal cell carcinoma.
Analyzing Caki-1 and 786-0 cells, the researchers were able to determine the effect of the V2R antagonist OPC31260 on cell viability, cell cycle, colonogenecity, and cell migration. Clear cell renal cell tumors (which along with papillary cell renal cell tumors represent between 70% and 75% of all renal cell carcinomas) tend to originate from the renal proximal tubules that express vasopressin type 1 receptors. However, in human clear cell renal cell tumors, the investigators detected V2R expression and V2R-mediated cell signaling.
“Since V2R activity promotes cell proliferation in polycystic kidney disease, we hypothesized that V2R activity is pathogenic in renal cell carcinoma, and V2R inhibition can suppress tumor growth,” the investigators noted.